Multiple Sclerosis (SM) is a chronic demyelinating disease of the central nervoussystem with immunological background. MS is most frequently diagnosed in people between 20 and 40 years of age, and this isinmost cases the relapsing — remitting form of the disease. Immunomodulatory therapy used in these patients isto reduce the frequency of relapses, thus the inhibition of progressive neurological disability and improvement of quality of life of patients is reached. At present in Poland the registered drugs in the treatmentof immunomodulatory relapsing — remitting form of multiple sclerosis include: interferons, glatiramer acetate, natalizumabifingolimod. The condition for the effectiveness of this therapy is to follow the rules of procedure...
The development of targeted therapies in AML patients enabling treatment individualization, such as ...
Introduction of tyrosine kinase inhibitors (TKI) in chronic myelogenous leukemia (CML) hassignifican...
Despite the significant progress in the treatment of haematological malignancies and the improvement...
Multiple Sclerosis (SM) is a chronic demyelinating disease of the central nervoussystem with immunol...
Multiple sclerosis is a demyelinating disease of the central nervous system. This disease has an imm...
Multiple sclerosis (Sclerosis Multiplex SM) is classified as a chronic disease. The first clinical s...
Multiple Sclerosis (SM) is the most common chronic inflammatory autoimmune demyelinating disease aff...
Szpiczak plazmocytowy jest uważany za chorobę niewyleczalną. Nowoczesne leczenie indukujące w sekwen...
Multiple sclerosis (SM) is an autoimmune, demyelinating disease of the central nervous system. The d...
Multiple sclerosis (MS) is an inflammatorydemyelinatingdisease of the central-nervous system with au...
Chronic kidney disease (CKD), as a systemic disease leading to body balance disturbance in both wate...
Introduction. Persistent therapy, i.e., long-term, and intensive treatment, which does not bring imp...
Treatment of chronic myelogenous leukemia (CML) with BCR-ABL1 tyrosine kinase inhibitors (TKI) signi...
Treatment of patients with refractory or relapse multiple myeloma (MM) is a major therapeutic challe...
Multiple sclerosis (MS) is chronic, immune-mediated inflammatory disease of the centralnervous syste...
The development of targeted therapies in AML patients enabling treatment individualization, such as ...
Introduction of tyrosine kinase inhibitors (TKI) in chronic myelogenous leukemia (CML) hassignifican...
Despite the significant progress in the treatment of haematological malignancies and the improvement...
Multiple Sclerosis (SM) is a chronic demyelinating disease of the central nervoussystem with immunol...
Multiple sclerosis is a demyelinating disease of the central nervous system. This disease has an imm...
Multiple sclerosis (Sclerosis Multiplex SM) is classified as a chronic disease. The first clinical s...
Multiple Sclerosis (SM) is the most common chronic inflammatory autoimmune demyelinating disease aff...
Szpiczak plazmocytowy jest uważany za chorobę niewyleczalną. Nowoczesne leczenie indukujące w sekwen...
Multiple sclerosis (SM) is an autoimmune, demyelinating disease of the central nervous system. The d...
Multiple sclerosis (MS) is an inflammatorydemyelinatingdisease of the central-nervous system with au...
Chronic kidney disease (CKD), as a systemic disease leading to body balance disturbance in both wate...
Introduction. Persistent therapy, i.e., long-term, and intensive treatment, which does not bring imp...
Treatment of chronic myelogenous leukemia (CML) with BCR-ABL1 tyrosine kinase inhibitors (TKI) signi...
Treatment of patients with refractory or relapse multiple myeloma (MM) is a major therapeutic challe...
Multiple sclerosis (MS) is chronic, immune-mediated inflammatory disease of the centralnervous syste...
The development of targeted therapies in AML patients enabling treatment individualization, such as ...
Introduction of tyrosine kinase inhibitors (TKI) in chronic myelogenous leukemia (CML) hassignifican...
Despite the significant progress in the treatment of haematological malignancies and the improvement...